Aspen, Amilco and Tiofarma are accused of taking part in an agreement that resulted in a price hike of fludrocortisone.
News
Video games encouraging ‘under the radar’ gambling
As it stands, 55,000 children are classed as having a gambling problem in the UK.
Tagrisso hit with NICE rejection for NSCLC
Unfortunately, the drug is not considered eligible for inclusion in the Cancer Drugs Fund either.
Opportunity awaits in the 2020 Clinical Researcher of the Year – The Americas competition
This annual competition has built up a strong reputation for uncovering the next set of talented clinical researchers currently working in North & South America.
Could beta-blockers slow the spread of cancer?
New research has suggested that the anti-stress drugs could stop cancer cells spreading through the body in women with breast cancer.
Robotic heart, heart attack vaccine among BHF Big Beat finalists
The remaining four teams will receive a small amount of seed funding – around £50,000 each – to help them win the £30 million funding award.
Cervical screening numbers hit ‘new low’
The “worrying trend” shows that less than three-quarters of women invited for cervical screening take it up.
QiC Dermatology now open for entries
QiC Programmes are run by PMGroup and were first launched in 2011 to bring the NHS, industry and patient groups closer together.
‘Make use of community pharmacists’, NICE urges
NICE is urging patients to ask their pharmacist advice about smoking, alcohol or maintaining a healthy weight.
Sunosi approved in Europe for EDS in narcolepsy, sleep apnoea
The European Commission has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness in the disorders.
PhoreMost enlists Otsuka in multi-project drug discovery collab
The partnership will have an initial focus on gene therapy applications of identified targets.
NICE rejects Janssen’s Stelara on cost efficiency grounds
The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.
Darzalex EU nod marks first newly diagnosed MM treatment in six years
The approval was based on results from part one of the Phase III CASSIOPEIA study.
Fight for Sight to fund macular degeneration research
As it stands, damage to the macula can’t be reversed, making it the most common cause of permanent and severe sight loss in the UK.
EU clears Roche’s Polivy for certain lymphomas
The drug has been approved in combination with bendamustine and MabThera.
